Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
    • Professional Training
      Insulin Pen Training
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool Diabetes & Cardiovascular Disease
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Utilizing Your EHR Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources
    • Support Program
      Diabetes Management Cardiovascular Risk Management
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg logo
Important Safety Information | Patient Site
Prescribing Information
    • Ozempic® Overview
    • Mechanism of Action
    • FAQs
    • Ozempic® and A1C
    • Ozempic® and Weight
    • Ozempic® vs Trulicity®
    • Ozempic® vs Lantus®
    • Special Populations
    • Safety Profile
    • Coffee With Coco Video Series
  • Cardiovascular Benefit
    • Dosing and Prescribing
    • Ozempic® Pen
  • Cost and Coverage
    • Samples
    • HCP Resources
    • Patient Resources
    • For Pharmacists
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg logo

Prescribing Information
Important Safety Information | Patient Site

NP Lisa Coco talks about type 2 diabetes management and Ozempic® with other leading experts

Watch full episodes

This program is sponsored by Novo Nordisk. NP Lisa Coco and her guests received a fee from Novo Nordisk Inc. for their participation in this video.

Sorry, your browser doesn't support embedded videos.


NP Lisa Coco talks about type 2 diabetes management and Ozempic® with other leading experts

Watch full episodes

This program is sponsored by Novo Nordisk. NP Lisa Coco and her guests received a fee from Novo Nordisk Inc. for their participation in this video.

Sorry, your browser doesn't support embedded videos.

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D and to reduce risk of major adverse CV events (MACE=CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2D and established CVD. Scroll below for Limitations of Use.

Hear from the experts

Join Lisa Coco for coffee—or tea, or whatever you like!—as  she and a few other experts dig into the topic of T2D management. They’ll be discussing Ozempic® study data, practice patterns they’ve observed in the field, and their own clinical experiences treating and supporting patients with type 2 diabetes.

Lisa Coco, nurse practitioner and host of Coffee with Coco

Lisa Coco
Nurse practitioner and expert in diabetes care

Meet Lisa

Lisa Coco is a nurse practitioner with 36 years of nursing experience. She initially specialized in critical care and trauma until a colleague in endocrinology recruited her into the specialty—and the rest is history! She now works in a university-based practice, as well as teaching, speaking, and hosting in-depth discussions with other T2D experts on the Coffee with Coco series.

Hear from the experts

Join Lisa Coco for coffee—or tea, or whatever you like!—as  she and a few other experts dig into the topic of T2D management. They’ll be discussing Ozempic® study data, practice patterns they’ve observed in the field, and their own clinical experiences treating and supporting patients with type 2 diabetes.

Meet Lisa

Lisa Coco is a nurse practitioner with 36 years of nursing experience. She initially specialized in critical care and trauma until a colleague in endocrinology recruited her into the specialty—and the rest is history! She now works in a university-based practice, as well as teaching, speaking, and hosting in-depth discussions with other T2D experts on the Coffee with Coco series.

Meet Lisa's guests

These providers come from a range of specialties and clinical environments. But they have one thing in common: they see Ozempic® as an appropriate choice for patients with type 2 diabetes who are ready for intensification of therapy.

Dr Carolina Solis-Herrera

Endocrinologist and Assistant Professor of Medicine

UT Health, San Antonio, TX


WATCH EPISODE

Dr James R Gavin III

Endocrinologist

Emory University, Atlanta, GA


WATCH EPISODE

Dr Joshua M. Stolker

Interventional cardiologist

Mercy Medical Group, St. Louis, MO


WATCH EPISODE

Dr Jennifer Goldman

Clinical pharmacist, CDCES, BC-ADM, FCCP

Massachusetts College of Pharmacy and Health Sciences, Boston, MA


WATCH EPISODE

Lisa Coco, NP

I’m a strong believer in Ozempic® for appropriate patients with T2D, and I hope this series will show you why.

Watch full episodes from the series

Watch the To-Go versions

Listen to the podcasts

Why I Prescribe Ozempic®

with Dr Carolina Solis-Herrera

Duration: 20:19

Released: 02/25/2022

Lisa and Dr Solis-Herrera talk T2D treatment algorithms, the SUSTAIN 7 study, and how their patients feel about injectable therapies.

When I'm teaching or speaking at a conference, the SUSTAIN 7 results are always an aha moment for the audience.

Why I Prescribe Ozempic®
(12:07)

Prescribing Information

Important Safety Information

Also available:

Watch the To-Go version »

Listen to the podcast »

Duration: 20:19

Released: 02/25/2022

Also available:

Watch the To-Go version (12:08) »

Listen to the podcast »

Lisa and Dr Solis-Herrera talk T2D treatment algorithms, the SUSTAIN 7 study, and how their patients feel about injectable therapies.

When I'm teaching or speaking at a conference, the SUSTAIN 7 results are always an aha moment for the audience.


Approaches to Injectable Therapy

with Dr James R. Gavin III

Duration: 23:35

Released: 02/25/2022

Lisa and Dr Gavin discuss the issue of clinical inertia in T2D treatment, and what the SUSTAIN 4 and SUSTAIN 5 studies say about Ozempic® and basal insulin.

We need to break the cycle of clinical inertia in the intensification of therapy for our patients with type 2 diabetes.

Approaches to Injectable Therapy
(13:27)

Prescribing Information

Important Safety Information

Also available:

Watch the To-Go version »

Listen to the podcast »

Duration: 23:35

Released: 02/25/2022

Also available:

Watch the To-Go version (13:40) »

Listen to the podcast »

Lisa and Dr Gavin discuss the issue of clinical inertia in T2D treatment, and what the SUSTAIN 4 and SUSTAIN 5 studies say about Ozempic® and basal insulin.

We need to break the cycle of clinical inertia in the intensification of therapy for our patients with type 2 diabetes.


The Role of Ozempic® in Cardiology

with Dr Joshua M. Stolker

Duration: 20:16

Released: 02/25/2022

Lisa and Dr Stolker discuss how and why he prescribes Ozempic® and his advice for others in cardiology who see patients with T2D and established cardiovascular disease.

I used to work with an appropriate patient's PCP or endocrinologist to start them on a GLP-1 RA like Ozempic®. But now, I prescribe Ozempic® myself.

()

Prescribing Information

Important Safety Information

Also available:

Watch the To-Go version »

Listen to the podcast »

Duration: 20:16

Released: 02/25/2022

Also available:

Watch the To-Go version (12:02) »

Listen to the podcast »

Lisa and Dr Stolker discuss how and why he prescribes Ozempic® and his advice for others in cardiology who see patients with T2D and established cardiovascular disease.

I used to work with an appropriate patient's PCP or endocrinologist to start them on a GLP-1 RA like Ozempic®. But now, I prescribe Ozempic® myself.


How Patient Support Can Help

with Dr Jennifer Goldman

Duration: 20:49

Released: 02/25/2022

Lisa and Dr Goldman compare their notes on how type 2 diabetes care has changed over time and what providers can do to help patients get off to a good start with Ozempic®.

Patients may think they’ll remember everything we talked about at a visit, but it’s great to have something to take home that also captures some of that.

How Patient Support Can Help
(11:25)

Prescribing Information

Important Safety Information

Also available:

Watch the To-Go version »

Listen to the podcast »

Duration: 20:49

Released: 02/25/2022

Also available:

Watch the To-Go version (11:26) »

Listen to the podcast »

Lisa and Dr Goldman compare their notes on how type 2 diabetes care has changed over time and what providers can do to help patients get off to a good start with Ozempic®.

Patients may think they’ll remember everything we talked about at a visit, but it’s great to have something to take home that also captures some of that.

Other ways to explore the content


Coffee To-Go

Watch bite-sized clips from the full episodes.

Prescribing Information | Important Safety Information
Ozempic® vs Trulicity® in SUSTAIN 7 with Dr Solis‑Herrera
(12:08)
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Ozempic® vs Trulicity® in SUSTAIN 7 with Dr Solis‑Herrera
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Clinical inertia in treating T2D with Dr Gavin
(13:40)
Clinical inertia in treating T2D with Dr Gavin
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Ozempic® and the SUSTAIN 6 CVOT with Dr Stolker
(12:02)
Ozempic® and the SUSTAIN 6 CVOT with Dr Stolker
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Ozempic® Patient Support with Dr Goldman
(11:26)
Ozempic® Patient Support with Dr Goldman
Watch video
Prescribing Information | Important Safety Information

Podcasts

Cue these up for your next coffee run.

(24:33)
Prescribing Information | Important Safety Information
Why I Prescribe Ozempic® with Dr Carolina Solis-Herrera
24:33
Why I Prescribe Ozempic® with Dr Carolina Solis-Herrera
Listen
Prescribing Information | Important Safety Information

(24:33)    

(27:54)
Prescribing Information | Important Safety Information
Approaches to Injectable Therapy with Dr James Gavin
27:54
Approaches to Injectable Therapy with Dr James Gavin
Listen
Prescribing Information | Important Safety Information

(27:54)    

(24:51)
Prescribing Information | Important Safety Information
The Role of Ozempic® in Cardiology with Dr Joshua Stolker
24:51
The Role of Ozempic® in Cardiology with Dr Joshua Stolker
Listen
Prescribing Information | Important Safety Information

(24:51)    

(21:43)
Prescribing Information | Important Safety Information
How Patient Support Can Help with Dr Jennifer Goldman
21:43
How Patient Support Can Help with Dr Jennifer Goldman
Listen
Prescribing Information | Important Safety Information

(21:43)    

Copy this address into your favorite podcast player:
http://coffeewithcoco.novomedlink.com/

Copy this address into your favorite podcast player:
http://coffeewithcoco.novomedlink.com/

Thanks for joining us! I hope these discussions have given you a fresh perspective on Ozempic® for appropriate patients with T2D.

Want to know more about starting your appropriate patients on Ozempic®?

Get Ozempic® samples for your appropriate patients

Request samples

Get details about dosing and prescribing within an EHR

See dosing and prescribing info

Looking for more about the topics covered on Coffee with Coco?

Looking for more about the topics covered here?

droplet, icon

Efficacy data from
SUSTAIN 7, 4, and 5

scale, icon

Ozempic® and weight

Ozempic® is not indicated for weight loss.

heart, icon

SUSTAIN 6 CVOT

patient resources, icon

Patient resources

Important Safety Information for Ozempic® (semaglutide) injection

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.

Indications and Limitations of Use

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease.

  • Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Ozempic® is not indicated for use in patients with type 1 diabetes mellitus.

Important Safety Information cont.

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®.

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
  • Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart. 
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
  • Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.
  • Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Drug Interactions

  • When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

Please click here for Ozempic® Prescribing Information, including Boxed Warning.

 

Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
    Professional Training
    • Insulin Pen Training
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
      Diabetes & Cardiovascular Disease
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Utilizing Your EHR
      Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
    Support Program
    • Diabetes Management
      Cardiovascular Risk Management

Ozempic®, Cornerstones4Care®, NovoCare®, NovoFine Plus®, NovoFine®, and NovoTwist® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22OZM00328 June 2022

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program